U.S. Food and Drug Administration (FDA) · United States
FDA External Drug Products
OTC external drug products covered by 21 CFR 358 (warts, corns and calluses, ingrown toenails, lice, dandruff, seborrheic dermatitis, psoriasis) may only claim the uses and actives in their monograph.
OTC external drug products covered by 21 CFR 358 (warts, corns and calluses, ingrown toenails, lice, dandruff, seborrheic dermatitis, psoriasis) may only claim the uses and actives in their monograph. Apply to US labeling, packaging and ads for OTC wart, corn/callus, ingrown toenail, lice, dandruff, seborrheic dermatitis and psoriasis products.
general_audience, general_adults_18plus, customers · OTC Drug · pharma
Where does this rule apply?
United States
Which marketing channels are covered?
all_channels
When does this rule take effect?
2026-05-10
What does this rule require?
OTC external drug products covered by 21 CFR 358 (warts, corns and calluses, ingrown toenails, lice, dandruff, seborrheic dermatitis, psoriasis) may only claim the uses and actives in their monograph.
How can marketing teams comply?
Apply to US labeling, packaging and ads for OTC wart, corn/callus, ingrown toenail, lice, dandruff, seborrheic dermatitis and psoriasis products.
OTC external drug products covered by 21 CFR 358 (warts, corns and calluses, ingrown toenails, lice, dandruff, seborrheic dermatitis, psoriasis) may only claim the uses and actives in their monograph.
Who does this rule apply to?
general_audience, general_adults_18plus, customers · OTC Drug · pharma
Supplements, cosmetics, foods and CBD products become unapproved drugs if their marketing claims to diagnose, treat, cure, mitigate or prevent disease, and cosmetics also may not claim to affect body structure or function.
Food and supplement labels may link a substance to reduced disease risk only through FDA-authorized or qualified health claims, in the required form, and only on foods meeting nutrient eligibility; disease treatment claims are not allowed.
Infant formula and baby food marketing must not be misleading, including claims of equivalence to breast milk, disease prevention, guaranteed development or absolute contaminant-free status; formulas must meet FDA nutrient and notification requirements.
Firm communications sharing scientific information on unapproved uses with HCPs must follow FDA's January 2025 final SIUU guidance: scientifically sound sources, required disclosures, no persuasive elements, and separation from promotion.
Prescription drug promotion must stay within the approved indication; information on unapproved uses may be shared only separately from promotion under FDA's safe-harbor guidance or in reply to unsolicited requests.
SaMD marketing must use the correct FDA status term (approved only for PMA devices, cleared for 510(k)), must not imply FDA endorsement or treat registration as approval, and must not claim uses beyond the authorized intended use.
Request a free compliance scan of your homepage and book a time with Warrant.